Tens of conspicuous Chinese healthcare companies, mainly from Greater China's biotech and health tech scene, will be trying luring the capitalists with their 2020 strategy at JPMorgan's phenomenal healthcare conference in San Francisco's Union Square. EqualOcean has compiled the list of companies whose executives will be giving keynote speeches on 15 January at Westin St. Francis Hotel.
While some of them are widely known in healthcare-focused investment circles, such as immuno-oncology developer Beigene and Ping An Holding's healthcare arm, some have yet to be explored by most of the attendees that will be attending the event.
Temasek-backed Transcenta, for instance, which carried out its Series B funding round, worth over USD 100 million on January 8 – the company is the out-licenser to Eli Lily of an antagonist for osteoporosis that has been developed (now in Phase II) for the Greater China Region.
LinkDoc, a state-backed Chinese medical data provider who constantly fails in transparency, is yet another eye-catching firm that will be scrutinized by the attendees. The company provides IT and big-data services to accelerate the drug-development and application processes for pharmaceuticals. The firm will present at the 'Emerging Markets Forum' of the event.
Immuno-oncology biotech Adagene, will be representing recently-proliferated Chinese immunotherapy startups. This Sequoia-backed firm also announced that it has secured over USD 70 million last week. I-Mab Biopharma, a Shanghai-based immuno-oncology firm that will be publicly traded on January 16 on NASDAQ, will be alluded to with this relatively smaller company.
There will be exponential growth-seeking small and young firms as well: Qiming-backed Ark Biosciences and oncology biotech Dizal Pharma executives will be speaking at the Westin St. Francis Hotel on the same day.
Around 38 Chinese firms – an increase of 22.6 percent over last year – have made presentations and attended one-on-one meetings at the three-day event in 2020, SCMP found. EqualOcean will be reporting on the event, particularly on the Chinese private health tech firms that have lately been seeking growth from overseas investors and markets.